Vistide

Country: European Union

Language: Bulgarian

Source: EMA (European Medicines Agency)

Buy It Now

Patient Information leaflet Patient Information leaflet (PIL)
19-01-2015
Summary of Product characteristics Summary of Product characteristics (SPC)
19-01-2015
Public Assessment Report Public Assessment Report (PAR)
19-01-2015

Active ingredient:

цидофовир

Available from:

Gilead Sciences International Limited

ATC code:

J05AB12

INN (International Name):

cidofovir

Therapeutic group:

Антивирусни средства за системно приложение

Therapeutic area:

Цитомегаловирусен ретинит

Therapeutic indications:

Vistide е показан за лечение на цитомегаловирусен ретинит при пациенти със синдром на придобита имунна недостатъчност (СПИН) и без бъбречна дисфункция. Vistide трябва да се използва само когато други средства се считат за неподходящи.

Product summary:

Revision: 21

Authorization status:

Отменено

Authorization date:

1997-04-23

Patient Information leaflet

                                21
Б. ЛИСТОВКА
Лекарствен продукт, който вече не е
разрешен за употреба
22
ЛИСТОВКА: ИНФОРМАЦИЯ ЗА ПОТРЕБИТЕЛЯ
VISTIDE 75 MG/ML КОНЦЕНТРАТ ЗА ИНФУЗИОНЕН
РАЗТВОР
Цидофовир (Cidofovir)
ПРОЧЕТЕТЕ ВНИМАТЕЛНО ЦЯЛАТА ЛИСТОВКА,
ПРЕДИ ДА ЗАПОЧНЕТЕ ДА ИЗПОЛЗВАТЕ ТОВА
ЛЕКАРСТВО.
-
Запазете тази листовка. Може да се
наложи да я прочетете отново.
-
Ако имате някакви допълнителни
въпроси, попитайте Вашия лекар или
фармацевт.
-
Това лекарство е предписано лично на
Вас. Не го преотстъпвайте на дру
ги хора. То може
да им навреди, независимо от това, че
техните симптоми са същите като
Вашите.
-
Ако някоя от нежеланите лекарствени
реакции стане сериозна или забележите
други,
неописани в тази листовка нежелани
реакции, моля уведомете Вашия лекар
или
фармацевт.
В ТАЗИ ЛИСТОВКА:
1.
Какво
представлява Vistide и за какво се
използва
2.
Преди да използвате Vistide
3.
Как да използвате Vistide
4.
Възможни нежелани реакции
5.
Как да съхранявате Vistide
6.
Допълнителна информация
1.
КАКВО ПРЕДСТАВЛЯВА VISTIDE И ЗА КА
КВО СЕ ИЗПОЛЗВА
VISTIDE СЕ ИЗПОЛЗВА ЗА ЛЕЧЕНИЕТО НА
ИНФЕКЦИЯ НА ОЧИТЕ, НАРЕЧЕНА CMV-РЕТИНИТ,
ПРИ
ПАЦИЕНТИ СЪС СПИН (СИНДРОМ НА
ПРИДОБИТАТА ИМУННА НЕДОСТАТЪЧНОСТ).
Vist
                                
                                Read the complete document

Summary of Product characteristics

                                1
ПРИЛОЖЕНИЕ I
КРАТКА ХАРАКТЕРИСТИКА НА ПРОДУКТА
Лекарствен продукт, който вече не е
разрешен за употреба
2
1.
ИМЕ НА ЛЕКАРСТВЕНИЯ ПРОДУКТ
Vistide 75 mg/ml концентрат за инфузионен
разтвор
2.
КАЧЕСТВЕН И КОЛИЧЕСТВЕН СЪСТАВ
Всеки ml съдържа 75 mg безводен цидофовир
(
_cidofovir_
). Всеки флакон съдържа 375 mg/5 ml
безводен цидофовир като активно
вещество.
Помощни вещества:
Всеки флакон съдържа приблизително 2,5
mmol (или 57 mg) натрий на флакон (5 ml) като
съставка от помощните вещества.
За пълния списък на помощните
вещества вижте точка
6.1.
3.
ЛЕКАРСТВЕНА ФОРМА
Концентрат за инфузионен разтвор.
Прозрачен разтвор.
Съставът е коригиран до pH 7,4.
4.
КЛИНИЧНИ ДАННИ
4.1
ТЕРАПЕВТИЧНИ ПОКАЗАНИЯ
Vistide е показан за лечението на
цитомегаловирусен (CMV) ретинит при
възрастни със
синдром на придобитата имунна
недостатъчност (СПИН) и без нарушения
на бъбречната
функция. Vistide трябва да бъде използван
само когато други лекарства
се сметнат за
неподходящи.
4.2
ДОЗИРОВКА И НА
ЧИН НА ПРИЛОЖЕНИЕ
Терапията трябва да бъде предписана
от лекар с опит в лечението на
HIV-инфекция.
Преди всяко прилагане на Vistide трябва
да бъдат изследвани нивата на
серумния креатинин и
на про
                                
                                Read the complete document

Similar products

Active ingredient цидофовир

цидофовир

ATC code J05AB12

J05AB12

Marketed by Gilead Sciences International Limited

Gilead Sciences International Limited

INN (International Name) cidofovir

cidofovir

Documents in other languages

Patient Information leaflet Patient Information leaflet Spanish 19-01-2015
Summary of Product characteristics Summary of Product characteristics Spanish 19-01-2015
Public Assessment Report Public Assessment Report Spanish 19-01-2015
Patient Information leaflet Patient Information leaflet Czech 19-01-2015
Summary of Product characteristics Summary of Product characteristics Czech 19-01-2015
Public Assessment Report Public Assessment Report Czech 19-01-2015
Patient Information leaflet Patient Information leaflet Danish 19-01-2015
Summary of Product characteristics Summary of Product characteristics Danish 19-01-2015
Public Assessment Report Public Assessment Report Danish 19-01-2015
Patient Information leaflet Patient Information leaflet German 19-01-2015
Summary of Product characteristics Summary of Product characteristics German 19-01-2015
Public Assessment Report Public Assessment Report German 19-01-2015
Patient Information leaflet Patient Information leaflet Estonian 19-01-2015
Summary of Product characteristics Summary of Product characteristics Estonian 19-01-2015
Public Assessment Report Public Assessment Report Estonian 19-01-2015
Patient Information leaflet Patient Information leaflet Greek 19-01-2015
Summary of Product characteristics Summary of Product characteristics Greek 19-01-2015
Public Assessment Report Public Assessment Report Greek 19-01-2015
Patient Information leaflet Patient Information leaflet English 19-01-2015
Summary of Product characteristics Summary of Product characteristics English 19-01-2015
Public Assessment Report Public Assessment Report English 19-01-2015
Patient Information leaflet Patient Information leaflet French 19-01-2015
Summary of Product characteristics Summary of Product characteristics French 19-01-2015
Public Assessment Report Public Assessment Report French 19-01-2015
Patient Information leaflet Patient Information leaflet Italian 19-01-2015
Summary of Product characteristics Summary of Product characteristics Italian 19-01-2015
Public Assessment Report Public Assessment Report Italian 19-01-2015
Patient Information leaflet Patient Information leaflet Latvian 19-01-2015
Summary of Product characteristics Summary of Product characteristics Latvian 19-01-2015
Public Assessment Report Public Assessment Report Latvian 19-01-2015
Patient Information leaflet Patient Information leaflet Lithuanian 19-01-2015
Summary of Product characteristics Summary of Product characteristics Lithuanian 19-01-2015
Public Assessment Report Public Assessment Report Lithuanian 19-01-2015
Patient Information leaflet Patient Information leaflet Hungarian 19-01-2015
Summary of Product characteristics Summary of Product characteristics Hungarian 19-01-2015
Public Assessment Report Public Assessment Report Hungarian 19-01-2015
Patient Information leaflet Patient Information leaflet Maltese 19-01-2015
Summary of Product characteristics Summary of Product characteristics Maltese 19-01-2015
Public Assessment Report Public Assessment Report Maltese 19-01-2015
Patient Information leaflet Patient Information leaflet Dutch 19-01-2015
Summary of Product characteristics Summary of Product characteristics Dutch 19-01-2015
Public Assessment Report Public Assessment Report Dutch 19-01-2015
Patient Information leaflet Patient Information leaflet Polish 19-01-2015
Summary of Product characteristics Summary of Product characteristics Polish 19-01-2015
Public Assessment Report Public Assessment Report Polish 19-01-2015
Patient Information leaflet Patient Information leaflet Portuguese 19-01-2015
Summary of Product characteristics Summary of Product characteristics Portuguese 19-01-2015
Public Assessment Report Public Assessment Report Portuguese 19-01-2015
Patient Information leaflet Patient Information leaflet Romanian 19-01-2015
Summary of Product characteristics Summary of Product characteristics Romanian 19-01-2015
Public Assessment Report Public Assessment Report Romanian 19-01-2015
Patient Information leaflet Patient Information leaflet Slovak 19-01-2015
Summary of Product characteristics Summary of Product characteristics Slovak 19-01-2015
Public Assessment Report Public Assessment Report Slovak 19-01-2015
Patient Information leaflet Patient Information leaflet Slovenian 19-01-2015
Summary of Product characteristics Summary of Product characteristics Slovenian 19-01-2015
Public Assessment Report Public Assessment Report Slovenian 19-01-2015
Patient Information leaflet Patient Information leaflet Finnish 19-01-2015
Summary of Product characteristics Summary of Product characteristics Finnish 19-01-2015
Public Assessment Report Public Assessment Report Finnish 19-01-2015
Patient Information leaflet Patient Information leaflet Swedish 19-01-2015
Summary of Product characteristics Summary of Product characteristics Swedish 19-01-2015
Public Assessment Report Public Assessment Report Swedish 19-01-2015
Patient Information leaflet Patient Information leaflet Norwegian 19-01-2015
Summary of Product characteristics Summary of Product characteristics Norwegian 19-01-2015
Patient Information leaflet Patient Information leaflet Icelandic 19-01-2015
Summary of Product characteristics Summary of Product characteristics Icelandic 19-01-2015

Search alerts related to this product

Alerts Vistide цидофовир cidofovir

Vistide цидофовир cidofovir

View documents history

Documents history Documents history

Vistide